anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a prospective cohort study. 200 subjects aged 18～75y with asymptomatic, mild, general-type COVID-19 will be recruited. The physiological parameters of wearable devices, including heart rate, sleep, blood oxygen saturation, electrocardiogram and exercise records, will be continuously collected from the day of admission / isolation to 14 days after discharge or out of quarantine. The Department of Respiratory and Critical Care of Peking University First Hospital is responsible for this research. All clinical data of patients during hospitalization will be collected including demographic characteristics, onset time, visit time, hospitalization time, symptoms, physical examination, laboratory examination, imaging characteristics, disease severity, treatment and outcome. Primary outcome is the deterioration of disease, the correlation analysis between the change of wearable device physiological parameters and the deterioration of disease determined by the traditional disease evaluation system will be used to find it whether can early alert deterioration of COVID-19.

The study protocol has been approved by the Peking University First Hospital Institutional Review Board (IRB) (2020-055). Any protocol modifications will be submitted for the IRB review and approval.
<P>PROBLEM TO BE SOLVED: To provide a means for maturating keratinocytes and increasing their areas.  <P>SOLUTION: An oral administration composition contains a promoter for keratinocyte maturation composed of α-linolenic acid, chondroitin sulfate or ceramide. Essence of a plant of the family Labiatae such as Perilla frutescens crispa, Perilla ocimoides is preferably cited as a source for the α-linolenic acid. Essence of shark cartilage is preferably cited as a source for the chondroitin sulfate. Essence of wheat and/or rice is preferably cited as a source for the ceramide. The oral administration composition raises the effect of a cosmetic.  <P>COPYRIGHT: (C)2004,JPO
Juvenile nasopharyngeal angiofibroma (JNA) is a rare paediatric tumour known for its local destructiveness and high recurrence rate. Surgery is the primary treatment modality for JNA, though other options, such as hormonal therapy, embolisation and radiotherapy, exist for inoperable cases. The location of the tumour makes surgical intervention challenging. A 14-year-old male presented with epistaxis and headaches as the chief complaints and was diagnosed with nasopharynx angiofibroma by computed tomography (CT) scan in 2018. Pre-operative embolisation was performed and followed by surgical removal of a 4 cm tumour in January 2019. Pathological examination revealed CD34 positivity, S100 negativity and Ki-67 positivity (5 to 10%), confirming angiofibroma. In October 2019, a 3.6 cm recurrent tumour was treated with embolisation and a second surgery. Pathological findings again confirmed JNA. The patient underwent four surgeries in total, but epistaxis persisted. In 2021, local radiotherapy was administered using intensity-modulated radiation therapy (IMRT) at a dose of 60 Gy in 25 fractions. Serial magnetic resonance imaging (MRI) post-radiotherapy showed a decreasing tumour size, with no further epistaxis and no observed radiation side effects 2 years post-treatment. Radiation therapy remains a strong alternative for managing recurrent JNA.
RATIONALE: Antiplatelet therapy (APT) is the standard of care after endovascular revascularization (EVR) in patients with peripheral artery disease (PAD). APT aims to prevent both major adverse cardiovascular events (MACE) and major adverse limb events (MALE). Nonetheless, the rates of MACE and MALE after EVR remain high. In coronary artery and cerebrovascular disease, dual APT (DAPT)compared to acetylsalicylic acid alone has been proven to reduce MACE without increasing the risk of major bleeding when applied for a restricted number of weeks. However, within the PAD population, insufficient data are available to understand the potential attributable effect of DAPT over single APT (SAPT). Therefore, prospective randomized studies in targeted study populations are warranted.
TRIAL DESIGN: CLEAR-PATH is a Dutch multicenter, double-blind, placebo-controlled, randomized trial comparing SAPT (clopidogrel 75 mg plus placebo) with DAPT (clopidogrel 75 mg plus acetylsalicylic acid 80 mg) in patients with PAD undergoing EVR. CLEAR-PATH includes a time-to-event analysis with a follow-up of one year. The primary composite efficacy endpoint consists of all-cause mortality, nonfatal stroke, nonfatal myocardial infarction, severe limb ischemia, (indication for) re-intervention due to any symptomatic restenosis, re-occlusion, or due to acute limb ischemia, and major amputation. The primary safety endpoint contains major bleeding following the Thrombolysis in Myocardial Infarction classification. The enrolment started in August 2022. In total 450 primary efficacy outcome events are required which expectedly amounts to 1696 subjects. Recruitment will take approximately 36 months.
CONCLUSION: CLEAR-PATH will assess the efficacy and safety of DAPT compared to SAPT following EVR in PAD patients.
TRIAL REGISTRATION NUMBER: NL80009.041.21.
For external use only. Not for ophthalmic use. Avoid contact with eyes, lips or mucous membranes. Do not use on areas of broken skin. If irritation or sensitivity occurs or infection appears, discontinue use. If swallowed, get medical help or contact a Poison Control Center right away. 

Application of lidocaine to larger areas or for longer times than those recommended could result in sufficient absorption of lidocaine resulting in serious adverse effects. 

Patients treated with class III anti-arrhythmic drugs (e.g., amiodarone, bretylium, sotalol, dofetilide) should be under close surveillance and ECG monitoring considered, because cardiac effects may be additive.

Lidocaine should be used with extreme caution in the presence of sepsis or severely traumatized mucosa in the area of application, since under such conditions there is the potential for rapid systemic absorption.
The invention provides a preparation method for sargassum confusum C.Ag. phlorotannins. The preparation method comprises the steps: evenly mixing dried sargassum confusum C.Ag. and a 40 vol% ethanol solution with the amount 20 times that of the dried sargassum confusum C.Ag., carrying out water bath extraction for 46 min at the temperature of 30 DEG C, centrifuging the extract liquid for 10 min at the speed of 4000 r/min, repeating extraction for 2 times, and thus obtaining a phlorotannins extract liquid. The method for optimizing the sargassum confusum C.Ag. phlorotannins best extraction conditions by a response surface method is used, and 3 independent variables comprising the ethanol volume fraction, the material-to-liquid ratio and the extraction time are set; screening is performed by using a Box-Benhnken response surface design principle; experimental design and result analysis are performed by using Design expert software; the exaction technology of the sargassum confusum C.Ag. phlorotannins improves the extraction rate of the phlorotannins, and plays an important role in industrialized production of the phlorotannins.
Apparently healthy individuals with an estimated screening number of approximately twenty-thousand individuals undergo an annual health exam in the investigators' hospital. The routine exam includes measurements of body height, body weight, blood pressure, visual and acoustic acuity, physical examinations, basic blood tests, urine analyses, chest radiography, and electrocardiography. The blood tests were performed after individuals fasted for at least eight hours. Individuals with any abnormal results underwent a clinical examination at an outpatient department for safety issues, ensuring the accuracy of the data. All data were registered prospectively. The investigators retrospectively collected data from the annual exam.
Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
Ethanol exposure during pregnancy is an important problem and is the cause of fetal alcohol syndrome (FAS) and fetal alcohol spectrum disorder (FASD). The etiology of FAS and FASD can be elucidated using animal models. Recently, a novel model, the zebrafish (Danio rerio), has garnered the interest of researchers. This study confirmed the negative influence of ethyl alcohol (0.5 %, 1.5 %, and 2.5 % v/v) on the development of zebrafish embryos. The observed malformations included pericardial and yolk sac edema, increased body curvature, tail edema, and a decreased embryo hatching rate. The differences in body length, body width, and heart rate were statistically significant. Due to the similarities in the quantity and function of ethanol biotransformation enzymes between zebrafish and mammals, this study investigated the nonoxidative metabolites of ethanol - ethyl glucuronide (EtG) and ethyl sulfate (EtS) - in zebrafish following ethanol exposure. This research confirmed that EtG and EtS concentrations can be measured in zebrafish embryos, and the levels of these metabolites appear to be associated with the ethyl alcohol concentration in the medium.
OBJECTIVES: The relationship between cognitive function and frailty in moyamoya disease (MMD) remains unclear, and the underlying mechanism is poorly understood. This study aims to investigate whether white matter hyperintensities (WMHs) mediate the association between frailty and cognitive impairment in MMD.
METHODS: Patients with MMD were consecutively enrolled in our study from January 2021 to May 2023. Pre-admission frailty and cognition were assessed using the Clinical Frailty Scale (CFS) and cognitive tests, respectively. Regional deep WMH (DWMH) and periventricular WMH (PWMH) volumes were calculated using the Brain Anatomical Analysis using Diffeomorphic deformation toolbox based on SPM 12 software. Multivariate logistic regression analysis was conducted to evaluate the association between frailty and cognitive function in MMD. Mediation analysis was performed to assess whether WMHs explained the association between frailty and cognition.
RESULTS: A total of 85 patients with MMD were enrolled in this study. On the basis of the CFS scores, 24 patients were classified as frail, 38 as pre-frail, and 23 as robust. Significant differences were observed in learning, memory, processing speed, executive functions, and semantic memory among the three groups (p < 0.001). Frailty was independently associated with memory and executive functions (p < 0.05); even after controlling for WMH. Mediation analysis indicated that the associations of frailty with memory and executive functions were partially mediated by WMH, DWMH, and PWMH (p < 0.05).
CONCLUSION: Frailty is significantly correlated with a higher risk of cognitive impairment in MMD, even after adjusting for other covariates. WMHs partially mediate the association between frailty and cognitive impairment.
Increases in serum transaminases (aspartate aminotransferase [AST]/serum glutamic-oxaloacetic transaminase, or alanine aminotransferase [ALT]/serum glutamic-pyruvic transaminase) have been reported with HMG-CoA reductase inhibitors, including fluvastatin. In most cases, the elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy. 

Approximately 1.1% of patients treated with fluvastatin capsules in worldwide trials developed dose-related, persistent elevations of serum transaminase levels to more than 3 times the upper limit of normal. Fourteen of these patients (0.6%) were discontinued from therapy. In all clinical trials, a total of 33/2969 patients (1.1%) had persistent transaminase elevations with an average fluvastatin exposure of approximately 71.2 weeks; 19 of these patients (0.6%) were discontinued. The majority of patients with these abnormal biochemical findings were asymptomatic. 

In a pooled analysis of all placebo-controlled studies in which fluvastatin capsules were used, persistent transaminase elevations (> 3 times the upper limit of normal [ULN] on two consecutive weekly measurements) occurred in 0.2%, 1.5%, and 2.7% of patients treated with daily doses of 20, 40, and 80 mg (titrated to 40 mg twice daily) fluvastatin capsules, respectively. Ninety-one percent of the cases of persistent liver function test abnormalities (20 of 22 patients) occurred within 12 weeks of therapy and in all patients with persistent liver function test abnormalities there was an abnormal liver function test present at baseline or by Week 8. 

In the pooled analysis of the 24-week controlled trials, persistent transaminase elevation occurred in 1.8% and 4.9% of patients treated with fluvastatin capsules 40 mg and fluvastatin capsules 40 mg twice daily, respectively. 

It is recommended that liver enzyme tests be performed prior to the initiation of fluvastatin, and if signs or symptoms of liver injury occur.

There have been rare postmarketing reports of fatal and nonfatal hepatic failure in patients taking statins, including fluvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with fluvastatin, promptly interrupt therapy. If an alternate etiology is not found do not restart fluvastatin.

In very rare cases, possibly drug-related hepatitis was observed that resolved upon discontinuation of treatment.1 Active liver disease or unexplained serum transaminase elevations are contraindications to the use of fluvastatin capsules [see Contraindications (4) and Warnings and Precautions (5.2)]. Caution should be exercised when fluvastatin is administered to patients with a history of liver disease or heavy alcohol ingestion [see Clinical Pharmacology (12.3)]. Such patients should be closely monitored.
Osmotherapy is commonly used in the treatment of intracranial hypertension (ICH) due to a variety of causes, including head trauma, intracranial neoplasia, infection or hemorrhage, and status epilepticus. The principle goal of osmotherapy is to shift fluid from the intracellular into the extracellular compartment using intravenous hyperosmolar agents, thereby reducing brain edema and improving cerebral perfusion pressure. Although 10-20% mannitol is considered the gold standard hyperosmolar agent in the treatment of ICH, mannitol-induced osmotic diuresis may cause hypovolemia and reduction in cerebral perfusion pressure. In recent years, 3.0-7.5% hypertonic saline (HTS) has gained popularity in the treatment of ICH as it has less pronounced diuretic effects and therefore does not cause hypovolemia. Indeed, in the face of hypovolemic shock and traumatic brain injury, HTS provides the advantage of volume expansion, restoring adequate cerebral perfusion pressures, and reducing brain edema, which makes it superior to mannitol in trauma patients with shock.

Both mannitol and HTS have been shown to interfere with whole blood coagulation and platelet function. This is in part due to dilutional coagulopathy. Furthermore, 7.2% HTS may directly disturb both fibrin formation and platelet function, and mannitol may interfere with coagulation by reducing clot strength. In addition, hyperosmolarity is supposed to lead to impairment of both whole blood coagulation and platelet function . In consequence, the safety of using these agents in patients with ICH and intracranial hemorrhage remains unclear. Previous in vitro studies in humans have demonstrated anticoagulant effects of both mannitol and HTS, although one clinical study failed to demonstrate any negative effect on hemostasis using either solution in patients undergoing elective intracranial surgery. However, in vivo studies in a clinical setting are lacking.
Money management is necessary for people with severe mental illness (SMI) to live safely in the community. Collective evidence has suggested that mental disorder leads to drift into poverty, is strong. Most of them struggle to meet basic needs with their existing income. Financial instability has been consistently linked to an increased risk of relapse. This experimental study aims to develop an internet-based self-help money management program that improve financial self-efficacy and its associated adverse outcomes among adult population with severe mental illness. Its efficacy will be compared with the wait-list control group. We hypothesized that (1) participants who received a money management program will improve financial self-efficacy after the intervention as compared with the wait-list controls; (2) participants from the money management program will have better financial well-being after the intervention as compared with the wait-list controls.

The online money management program course will consist of 4 weekly modules, incorporating the key components of money management and the Model of Human Occupation (MOHO), including the concept of money management, money management skill, and risk of financial exploitation. Each module will consist of the main component presented in video format, quiz, and homework. Materials will be presented interactively to facilitate engagement.
Renal complications, including irreversible renal failure have been reported in patients receiving mannitol. Reversible, oliguric acute kidney injury has occurred in patients with normal pretreatment renal function who received large intravenous doses of mannitol. Although the osmotic nephrosis associated with mannitol administration is in principle reversible, osmotic nephrosis in general is known to potentially proceed chronic or even end-stage renal failure. Monitor renal function closely, including signs of urine output reduction, during Mannitol Injection infusion. Patients with pre-existing renal disease, patients with conditions that put them at high risk for renal failure, or those receiving potentially nephrotoxic drugs or other diuretics, are at increased risk of renal failure following administration of Mannitol Injection. Avoid concomitant administration of nephrotoxic drugs (e.g., aminoglycosides) or other diuretics with Mannitol Injection, if possible [see Drug Interactions (7.1, 7.2)].

Patients with oliguric acute kidney injury who subsequently develop anuria while receiving mannitol are at risk of congestive heart failure, pulmonary edema, hypertensive crisis, coma and death.

During and following Mannitol Injection infusion for the reduction in intracranial pressure, monitor the patient clinically and review laboratory tests for changes in fluid and electrolyte status. Discontinue Mannitol Injection if renal function worsens [see Warnings and Precautions (5.5)].
The present invention provides a solution to backhauling health information. The present invention utilizes a mesh network to backhaul the health information. The system includes a plurality of first tags, a mesh network, and an information engine. Each of the tags represents a first object. The mesh network preferably includes a plurality of plug-in sensors located within the facility. At least one node in the mesh network operates as healthcare device. The information engine is in communication with the mesh network and determines a position location of the healthcare device and an operation of the healthcare device.
PURPOSE: To obtain an aerosol component containing a powder, comprising a microencapsulated perfume and a specific powdery dispersant, capable of sustaining an aroma after use and good in dispersibility of the powder and usability. CONSTITUTION: This aerosol composition containing a powder contains a perfume microencapsulated with a water-soluble glucide and a powdery dispersant comprising a sorbitan ester of a fatty acid and/or a polyoxyalkylene alkyl ether in an amount of (1/50) to (1/20)wt.% based on the whole powder in the aerosol composition containing the powder, a liquefied petroleum gas and an inorganic and/or an organic powder. The microcapsule contains the encapsulated perfume (e.g. menthol or citrus) in an amount of 5-80wt.% based on the whole microcapsule and has <=250μm size. The liquefied petroleum gas used as a propellant consists essentially of propane, n-butane, etc. The amount thereof blended is 50-95wt.% and that of the powder is 0.1-30wt.%. The composition is prepared into a deodorant powder spray, a powder Cologne spray, etc., for use.
FIELD: cosmetic preparations. SUBSTANCE: the method deals with hair cosmetic compositions which contain a single cation polymer and a triple acrylic one at cosmetically acceptable water medium. A triple acrylic polymer contains: about 20-70 weight% α, β- monoethylene unsaturated carboxylic acid, about 20-80 weight% monoethylene unsaturated monomer with no surface-active properties and about 0.5-60 weight% nonionic urethane monomer being the reaction product of nonionic surface-active substance which contains one mobile hydrogen atom with monoethylene unsaturated monoisocyanate. Being in a permanent form, these cosmetic preparations contain quaternized and nonquaternized copolymers of vinylpyrrolidone and dialkylaminoalkylacrylate or dialkylaminoalkylmetacrylate, or quaternized polymers of vinylpyrrolidone and vinylimidazole. EFFECT: improved hair softness, naturalness by touch at higher fixing properties of preparation. 19 cl
An electronic, hand-held, easy-to-use, icon driven medical log that can be easily used by the elderly, children, the sick, the incapacitated and those with minimal computer skills. The medical log includes a first set of icons each representative of a different bodily condition and a second set of icons each representative of a different bodily location. A third set of icons is also provided to control the operation of the medical log. The medical log is initialized by programming the date and time into the device using the control icons. Once the medical log is initialized, a patient or a caretaker can make entries into the medical log by entering a bodily condition by selecting one of the first set of icons. The bodily location where the patient is experiencing discomfort is then entered into the medical log by selecting one of the second set of icons. The date and time the condition and bodily location was entered into the medical log is automatically stored in the log for later retrieval. Entries into the medical log can be made at prescheduled times each day or whenever the patient is experiencing discomfort. By consistently entering such information, an accurate log including the date, time, condition and location of the patient's ailments are recorded. Since information is entered into the log in a simple two-step operation using easy-to-understand icons, almost any patient or caretaker, regardless of their lack of computer skills or medical condition, can successfully use the present invention.